Navigation Links
Emisphere to Host Business Strategy Conference Call on February 7
Date:1/31/2008

- CEO Michael V. Novinski to Discuss Plans for Company in 2008 and Beyond -

CEDAR KNOLLS, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), announced today that it will host a teleconference on Thursday, February 7, at 10:00 AM EST. President and Chief Executive Officer Michael V. Novinski will discuss the company's emerging business strategy. Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology.

A live Webcast of the conference call can be accessed through the company's web site at http://www.emisphere.com. The live conference call dial-in number is: 1-888-264-8952 (U.S. and Canada) or 1-913-312-0654 (International). In addition, an archive of the Webcast can be accessed through the same link; an audio replay of the call will be available following the conference call by calling 1-888-203-1112 (U.S. and Canada) or 1-719-457-0820 (International). The conference replay PIN is 871428. A slide deck will be available on the Emisphere web site at the time of the call.

"Emisphere's investor base is a valued resource," said Michael V. Novinski, President and Chief Executive Officer of Emisphere Technologies, Inc. "Our teleconference will provide investors with a better understanding of where we are taking the company and what opportunities lie ahead."

About Emisphere Technologies, Inc.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its eligen(R) technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The Web site is http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no. 000-17758) and for the quarter ended June 30, 2007, filed on August 7, 2007 (file No. 000-17758).


'/>"/>
SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
2. Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
3. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
4. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
5. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. Medefield Announces New Appointments to North American Business Unit
8. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
9. Clinimetrics Celebrates 20th Anniversary in Contract Research Business
10. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
11. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2016)... ... 2016 , ... Doctors in Rome say micronutrients found in certain foods have ... Mesothelioma has just posted an article on the new research. Click here to ... Sciences and Translational Medicine evaluated more than 150 studies on polyphenols in cancer for ...
(Date:5/20/2016)... ... May 20, 2016 , ... The recent recall by Costco and ... Food Safety News on May 12, 2016(1), demonstrates the need for faster and more ... Baltimore-based biotech firm, PathSensors, Inc. , PathSensor’s latest solution uses a ...
(Date:5/19/2016)... ... May 19, 2016 , ... ... (CRO) has welcomed Abu Siddiqui as Director, Large Molecule & Biomarker Bioanalysis. , ... vaccine and translational biomarker discovery studies for preclinical and clinical safety programs. “We’ve ...
(Date:5/18/2016)... ... May 18, 2016 , ... ... Camp at The University of Toledo. This two-day camp will take place annually ... explore the field of pharmaceutical sciences in preparation for a university academic program. ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):